title: Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.
authors.affiliation: Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia frederick.lee@sswahs.nsw.gov.au.
authors.forename: F J
authors.initials: FJ
authors.lastname: Lee
authors.affiliation: HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Marriott
authors.affiliation: Holdsworth House Medical Practice, Sydney, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Bloch
authors.affiliation: Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Richardson
authors.affiliation: Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
authors.forename: N
authors.initials: N
authors.lastname: Mackenzie
authors.affiliation: Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Carr
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000069454:Darunavir / Q000009:adverse effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism* / Q000821:virology; D015497:HIV-1; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D000068898:Raltegravir Potassium / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D000068898:Raltegravir Potassium; D019438:Ritonavir; D000069454:Darunavir